The Effect of Risedronate on Bone Mineral Density in Postmenopausal Women

林华,包丽华,李滨,刘树琴,于浩

DOI: https://doi.org/10.3969/j.issn.1006-7108.2007.10.012

2007-01-01

Abstract:Objective The purpose of the present study was to evaluate the therapeutic effect on bone mineral density (BMD) of risedronate in postmenopausal osteoporotic women. Methods 223 postmenopausal patients were randomly divided into two administration groups: group A (risedronate, 5 mg/day, daily) and group B (placebo, daily). They received either risedronate (5 mg/day, orally) or placebo for up to 1 year. All subjects received calcium and vitamin D supplementation. The BMD of the lumbar spine (L_2～L_4) and hip (neck, trochanter and Ward's) were measured by dual-energy X-ray absorptiometry at baseline, 6 months, and 12 months after treatment. The patients were followed up every 3 mo for 12 mo, BMD measurements were taken at baseline, 6mo and at the end of the study. Results At baseline, both risedronate and placebo groups patients had bone mineral density (BMD) 1.0 SD or more below the young adult women mean. There were no significant differences in age, body mass index, BMD at baseline between the two groups. At the end of the study, there were statistically significant increases in BMD in group A at two sites at lumbar spine and neck of hip (P0.05). Conclusions Risedronate apparently has a statistically significant therapeutic effect on bone mineral density (BMD) on lumbar and hip for prevention and treatment of postmenopausal osteoporosis.